{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:40:45Z","timestamp":1772214045880,"version":"3.50.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Biomarker directed selection of targeted anti-neoplastic agents such as immune checkpoint inhibitors, small molecule inhibitors and monoclonal antibodies form an important aspect of cancer treatment. Immunohistochemistry (IHC) analysis of the tumor tissue is the method of choice to evaluate the presence of these biomarkers. However, a significant barrier to biomarker testing on tissue is the availability of an adequate amount of tissue and need for repetitive sampling due to tumor evolution. Also, tumor tissue testing is not immune to inter- and intra-tumor heterogeneity. We describe the analytical and clinical validation of a Circulating Tumor Cell (CTC) assay to accurately assess the presence of PD-L1 22C3 and PD-L1 28.8, ER, PR and HER2, from patients with solid tumors to guide the choice of suitable targeted therapies. Analytically, the test has high sensitivity, specificity, linearity and precision. Based on a blinded case control study, the clinical sensitivity and specificity for PD-L1 (22C3 and 28.8) was determined to be 90% and 100% respectively. The clinical sensitivity and specificity was 83% and 89% for ER; 80% and 94% for PR; 63% and 89% for HER2 (by ICC); and 100% and 92% for HER2 (by FISH), respectively. The performance characteristics of the test support its suitability and adaptability for routine clinical use.<\/jats:p>","DOI":"10.1371\/journal.pone.0270139","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:28:44Z","timestamp":1655472524000},"page":"e0270139","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers"],"prefix":"10.1371","volume":"17","author":[{"given":"Raymond","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshana","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dadasaheb","family":"Akolkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudha S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Bendale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revati","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Fulmali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Fulmali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Adhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Puranik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Apurwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirantan","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-9728","authenticated-orcid":true,"given":"Jinumary","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Datar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"3","key":"pone.0270139.ref001","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cmrp.2017.04.002","article-title":"An overall review of targeted therapy in solid cancers","volume":"7","author":"V Talwar","year":"2017","journal-title":"Curr Med Res Pract"},{"issue":"4","key":"pone.0270139.ref002","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"SP Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"pone.0270139.ref003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"J Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"pone.0270139.ref004","first-page":"985","article-title":"Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?","volume":"10","author":"KM Kerr","year":"2015","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"6","key":"pone.0270139.ref005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular biology in breast cancer: intrinsic subtypes and signaling pathways","volume":"38","author":"P Eroles","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"pone.0270139.ref006","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"TO Nielsen","year":"2004","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"6797","key":"pone.0270139.ref007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"CM Perou","year":"2000","journal-title":"Nature"},{"issue":"19","key":"pone.0270139.ref008","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"T S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0270139.ref009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","article-title":"Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry","volume":"21","author":"S Park","year":"2012","journal-title":"Breast"},{"issue":"21","key":"pone.0270139.ref010","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"pone.0270139.ref011","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.21873\/anticanres.13389","article-title":"The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer","volume":"39","author":"C Vogel","year":"2019","journal-title":"Anticancer Res"},{"issue":"6","key":"pone.0270139.ref012","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1159\/000506464","article-title":"Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype","volume":"15","author":"I Holzer","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"pone.0270139.ref013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-010-1029-2","article-title":"HER2 status in a population-derived breast cancer cohort: discordances during tumor progression","volume":"125","author":"U Wilking","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"pone.0270139.ref014","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/jco.2013.31.15_suppl.1039","article-title":"Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor","volume":"31","author":"H-C Shin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0270139.ref015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"T Grinda","year":"2021","journal-title":"NPJ breast cancer"},{"issue":"Suppl 7","key":"pone.0270139.ref016","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/annonc\/mds232","article-title":"Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"F Cardoso","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"pone.0270139.ref017","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer","volume":"30","author":"E Amir","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"24","key":"pone.0270139.ref018","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"33","author":"C Van Poznak","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"pone.0270139.ref019","unstructured":"NCCN Guidelines: Breast Cancer version 2.2022 [Internet]. nccn.org. [cited 2022 Jan 1]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"6","key":"pone.0270139.ref020","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bju.13586","article-title":"Liquid biopsy: ready to guide therapy in advanced prostate cancer?","volume":"118","author":"M Hegemann","year":"2016","journal-title":"BJU Int"},{"key":"pone.0270139.ref021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fonc.2019.00129","article-title":"The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer","volume":"9","author":"J Saarenheimo","year":"2019","journal-title":"Front Oncol"},{"issue":"155","key":"pone.0270139.ref022","article-title":"Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages","volume":"29","author":"N Guibert","year":"2020","journal-title":"Eur Respir Rev an Off J Eur Respir Soc"},{"issue":"12","key":"pone.0270139.ref023","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/ijc.32815","article-title":"Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer","volume":"146","author":"D Akolkar","year":"2020","journal-title":"Int J cancer"},{"issue":"3","key":"pone.0270139.ref024","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncy.22366","article-title":"Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging","volume":"129","author":"A Gaya","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"pone.0270139.ref025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00280-020-04189-8","article-title":"Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors","volume":"87","author":"T Crook","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"pone.0270139.ref026","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"AC Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"pone.0270139.ref027","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"E Valtorta","year":"2015","journal-title":"Mod Pathol an Off J United States Can Acad Pathol Inc"},{"issue":"6","key":"pone.0270139.ref028","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"A Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0270139.ref029","doi-asserted-by":"crossref","first-page":"599894","DOI":"10.3389\/pore.2021.599894","article-title":"Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent\/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases","volume":"27","author":"L Peng","year":"2021","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"pone.0270139.ref030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2012-0350","article-title":"Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis","volume":"18","author":"E Curtit","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"pone.0270139.ref031","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s12032-013-0798-y","article-title":"Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis","volume":"31","author":"Z-X Yao","year":"2014","journal-title":"Med Oncol"},{"key":"pone.0270139.ref032","first-page":"515","article-title":"Discordance of the estrogen receptor and HER-2\/neu in breast cancer from primary lesion to first and second metastatic site","volume":"9","author":"EE Lower","year":"2017","journal-title":"Breast cancer (Dove Med Press"},{"issue":"1","key":"pone.0270139.ref033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-018-9950-6","article-title":"Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases","volume":"36","author":"QF Manson","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"pone.0270139.ref034","doi-asserted-by":"crossref","first-page":"102257","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis","volume":"99","author":"C Boman","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"pone.0270139.ref035","doi-asserted-by":"crossref","first-page":"100353","DOI":"10.1016\/j.ctarc.2021.100353","article-title":"Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas","volume":"27","author":"JR Naso","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"8","key":"pone.0270139.ref036","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080809","article-title":"Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC","volume":"8","author":"V Kloten","year":"2019","journal-title":"Cells"},{"key":"pone.0270139.ref037","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/CMAR.S245425","article-title":"Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer","volume":"12","author":"Y Cheng","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1","key":"pone.0270139.ref038","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"M Ili\u00e9","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"pone.0270139.ref039","doi-asserted-by":"crossref","first-page":"1738798","DOI":"10.1080\/2162402X.2020.1738798","article-title":"Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)","volume":"9","author":"S Bergmann","year":"2020","journal-title":"Oncoimmunology"},{"issue":"15","key":"pone.0270139.ref040","doi-asserted-by":"crossref","first-page":"e15031","DOI":"10.1200\/JCO.2021.39.15_suppl.e15031","article-title":"Circulating tumor cell proportion scoring (CTPS) based PD-L1 assessment and clinical application of circulating tumor cells (CTCs) on stage IV non-small cell lung cancer (NSCLC) through liquid biopsy","volume":"39","author":"MY Choi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0270139.ref041","first-page":"539","article-title":"Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients","volume":"17","author":"K Kalinsky","year":"2015","journal-title":"Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex"},{"issue":"6","key":"pone.0270139.ref042","doi-asserted-by":"crossref","first-page":"100299","DOI":"10.1016\/j.esmoop.2021.100299","article-title":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program","volume":"6","author":"V M\u00fcller","year":"2021","journal-title":"ESMO open"},{"issue":"10","key":"pone.0270139.ref043","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.bjc.6605676","article-title":"Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer","volume":"102","author":"LM Flores","year":"2010","journal-title":"Br J Cancer"},{"issue":"15","key":"pone.0270139.ref044","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/jco.2012.30.15_suppl.584","article-title":"Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy","volume":"30","author":"FZ Bischoff","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0270139.ref045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-016-2587-4","article-title":"Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients","volume":"16","author":"B Aktas","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"pone.0270139.ref046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cam4.70","article-title":"Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer","volume":"2","author":"S Krishnamurthy","year":"2013","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0270139.ref047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00023","article-title":"Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer","author":"A De Gregorio","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"pone.0270139.ref048","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdy211","article-title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091\u201310093, BIG 1\u201312, Treat CTC): a randomized phase II trial","volume":"29","author":"M Ignatiadis","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"pone.0270139.ref049","first-page":"12","article-title":"Abstract PD3-12: Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells\u2014results from the randomized phase III DETECT III trial","author":"T Fehm","year":"2021","journal-title":"PD3"},{"issue":"11","key":"pone.0270139.ref050","doi-asserted-by":"crossref","first-page":"e0260124","DOI":"10.1371\/journal.pone.0260124","article-title":"PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer","volume":"16","author":"EP Darga","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"pone.0270139.ref051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082885","article-title":"Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells","volume":"21","author":"C Forsare","year":"2020","journal-title":"Int J Mol Sci"},{"key":"pone.0270139.ref052","doi-asserted-by":"crossref","first-page":"734595","DOI":"10.3389\/fgene.2021.734595","article-title":"Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response","volume":"12","author":"J Liu","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"pone.0270139.ref053","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.clbc.2018.10.009","article-title":"Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer","volume":"19","author":"W Chen","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"pone.0270139.ref054","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41379-020-0555-7","article-title":"The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.","volume":"33","author":"G Farshid","year":"2020","journal-title":"Mod Pathol an Off J United States Can Acad Pathol Inc"},{"issue":"1","key":"pone.0270139.ref055","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clbc.2021.05.004","article-title":"Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression\/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study","volume":"22","author":"R Memon","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"pone.0270139.ref056","first-page":"3323","article-title":"Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer","volume":"37","author":"D Furrer","year":"2017","journal-title":"Anticancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:26:10Z","timestamp":1727396770000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270139"}},"subtitle":[],"editor":[{"given":"Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0270139","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202201.0380.v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}